

"Express Mail" Label No. EV 338 440 643 US  
Date of Deposit May 21, 2003

hereby certify that this is being deposited with the United States Postal  
Service "Express Mail Post Office to Address" service under 37 CFR 1.10  
on the date indicated above and is addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

By: Rosemarie L. Celli

Rosemarie L. Celli

PATENT  
Attorney Docket No.: 015270-005912US  
Client Reference No.: 209-US-NEW6C2

RECEIVED

MAY 30 2003

CH CENTER 1600/2900

#14  
B.G.J.  
6/12/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/724,575

Filed: November 28, 2000

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Christopher J. Nichols

Art Unit: 1647

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08B form are being called to the  
attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that  
the cited references be expressly considered during the prosecution of this application, and the  
references be made of record therein and appear among the "references cited" on any patent to  
issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a  
search has been conducted or that this statement encompasses all the possible relevant  
information, and no inference should be made that the information and references cited are, or  
are considered to be material to patentability because they are in this statement. No inference

Dale B. Schenk  
Application No.: 09/724,575  
Page 2


should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed after the first office action was mailed but before the mailing date of the final office action or the notice of allowance. Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

CERTIFICATION


I hereby certify that no item of information contained in the Supplemental Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the undersigned's knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Respectfully submitted,



Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC:rlc



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005912US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CS	349	CLARK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003).	—
CS	350	Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- $\beta$ peptide: a case report," <u>Nature Medicine</u> , 9(4):448-452 (April 2003).	—

RECEIVED

MAY 30 2003

TECH CENTER 1600/2900

Examiner Signature		Date Considered	7/14/03
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.